Zogenix (ZGNX)

[chestnut42]

From the Motley Fool "4 Stories to Watch This Week in the Health-Care Sector"


As we close in on the end of the year, news stories in the health-care sector tend to get a bit scarcer. However, this week we still have four worthwhile events to keep our attention.

First up, in the biotech sector, we have an FDA panel meeting scheduled on Friday for Zogenix (Nasdaq: ZGNX ) and its around-the-clock, oral, pain-management drug, Zohydro ER, which uses hydrocodone without acetaminophen (a common drug that can cause liver toxicity if used excessively). In August, Zogenix reported positive phase 3 results demonstrating that the drug met its two primary endpoints: the proportion of patients with a minimum of 30% improvement in pain tolerability and satisfaction with the medication. My guess is that with few safety concerns and having been well tolerated in trials, there probably won't be too much in the way of negative news during the panel review.